Study Of Infusion Drug Mark-Ups Suggests Misuse Of 340B Program

By Gabrielle Wanneh / January 25, 2024 at 7:26 PM
A new study published Thursday (Jan. 25) in the New England Journal of Medicine found that at hospitals participating in the 340B drug discount program, price markups for some of the most used doctor-administered infusion drugs between 2020 and 2021 were 6.59 times higher than the markups seen at independent doctor practices, while the markups at non-340B hospitals were 4.34 times higher than those at the same physician practices. Researchers at the University of California, Berkeley, who authored the...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.